Italian researchers have reported that combining thymidine labeling with HER-2 analysis can assist in assigning risk of relapse to patients with node-negative breast cancer receiving loco-regional treatment only. This report appeared in the July 15 2003 issue of the Journal of Clinical Oncology.
|
All times are GMT -7. The time now is 07:07 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021